Analysis | The Health 202: One GOP senator is urging the drug industry to make good on lowering prices

  • 📰 washingtonpost
  • ⏱ Reading Time:
  • 70 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 31%
  • Publisher: 72%

Business News News

Business Business Latest News,Business Business Headlines

The Health 202: One GOP senator is urging the drug industry to make good on lowering prices

allowing drug companies to offer discounted prices directly to consumers, aiming to stop the controversial rebate practice. But those rules would apply only to Medicare drug plans and Medicaid managed-care plans.

During last week’s testimony by drug executives before the Senate Finance Committee, Chairman Chuck Grassley asked whether their companies would lower prices if the Trump rule applying to public-sector plans is ultimately implemented. they would be willing to lower prices if rebates were banned in the private sector, too.

During the hearing, Bristol-Myers Squibb chief executive Giovanni Caforio said he shared the same position. After a follow-up question, Bristol-Myers Squibb said it remains “committed to working with Congress and the Administration on reforming the rebate system with a focus on what is best for patients.”After the hearing, Sen.

"[T]he legislation appears to do absolutely nothing to address the root cause of the problem: high list prices that only the drug manufacturers have the power to set," J.C. Scott, president of the Pharmaceutical Care Management Association, told The Health 202 in a statement."Despite drug manufacturers’ rhetoric, their pricing strategies are unrelated to the rebates they negotiate with PBMs.

“This bill doesn’t outlaw PBMs. It doesn’t even outlaw rebates. What it’s going to do is shed light on the process so they’re not going to be able to get by with the argument that there’s room for a whole other layer of a middleman,” Braun said. “You don’t need it."AHH, OOF and OUCH

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Key figure in this tweet: '1' Only ONE single Republican senator is actually pushing for what the GOP promised. One. Progress? 🇷🇺🐘💩

The pharmacy industry has proven , again and again, that it is a predatory monopolistic industry. Serious regulation is necessary.

Isn’t he the guy that defeated Joe Donnelly (D) last November? 😏

The GOP thinks they can just ask corporations nicely to do the right thing even though there are very few cases that ever happens

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 95. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Analysis | The Health 202: Republicans appear open to the administration's Medicare threat to the pharmaceutical industryThe Health 202: Republicans appear open to the administration's Medicare threat to the pharmaceutical industry How about repealing the law that actually makes it illegal for Medicare to negotiate with drug companies? ТЕБЕ КАЖЕТСЯ This would be better than the nothing we have now so let’s do it. Make it happen Mr President
Source: washingtonpost - 🏆 95. / 72 Read more »

Mental health app makers join forces to go after multibillion-dollar marketAbleTo, a start-up with a network of licensed therapists and coaches, acquired Joyable, the latest in a string of recent deals in mental health. It will fail, if their goal was to help the mentally ill I would have said yea but their goal is to make money
Source: CNBC - 🏆 12. / 72 Read more »

Three stocks to buy for a health-care comebackHealth-care stocks are trailing the S&P 500, but investors could find profits in some medical device plays, says stock-picking expert Matt Maley. how come those health-care companies will be survive under Democrat socialist agenda ? 😎
Source: CNBC - 🏆 12. / 72 Read more »